Axogen
Axogen's revenue rose 20.2% to $225 million in fiscal 2025. Its operating margin was −3.5%, down from −1.8% a year earlier. Free cash flow was −$3 million, against $1 million a year earlier. The diluted share count rose 4.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Axogen does
Axogen makes products to repair damaged peripheral nerves, the nerves that carry movement and feeling signals through the body. Surgeons use them after injuries or operations that cut or damage a nerve. Its Avance nerve graft is a processed human nerve that bridges a gap between severed nerve ends. In December 2025 the FDA approved a newer version, Avance, which Axogen expects to launch in the second quarter of 2026.
It also sells Axoguard products made from pig tissue: a connector, protectors and a cap, which join, wrap or cap nerves during repair. Axogen sells to surgeons and healthcare providers, and depends on payments from public and private insurers. Avance products make up about 60% of its revenue.
Axogen says its business is focused specifically on the science, development and sale of technologies for peripheral nerve regeneration and repair.
Its biggest risks, as it describes them
- A large share of revenue comes from Avance products, so an adverse FDA decision would hurt it.
- Its revenue depends on a small number of products.
- Its revenue depends on prompt and adequate reimbursement from insurers and health systems.
- Problems at its processing facility could limit supply.
- It has a history of net losses and has not consistently produced positive cash flow.
Income statement
Axogen lost money in fiscal 2025: a net loss of $16 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 84 | 49 | 31 | 34 | 42 |
| Debt incl. finance leases | 45 | 46 | 47 | 48 | 48 |
| Net debt (negative means net cash) | −39 | −3 | 16 | 14 | 7 |
| Net debt to EBITDA | — | — | — | 4.4x | — |
| Debt to equity | 0.4x | 0.5x | 0.5x | 0.5x | 0.4x |
| Interest coverage | −18.7x | −47.6x | −7.6x | −0.4x | −1.0x |
| Current ratio | 5.2x | 4.1x | 2.9x | 3.2x | 5.1x |
| Quick ratio | 4.5x | 3.3x | 2.1x | 2.2x | 3.3x |
Cash flow
Projections
Project Axogen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Axogen shares on the open market, and 11 insiders sold $17.1 million, $4.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Joseph A. TyndallDirector | Sold plan | 3,500 | $49.70 | $173,950 | Form 4 |
| Aug 11, 2026 | Amy McBride WendellDirector | Sold plan | 13,353 | $48.42 | $646,552 | Form 4 |
| Aug 10, 2026 | Marc A BeganEVP & General Counsel | Sold plan | 67,500 | $47.35 | $3.2 million | Form 4 |
| Aug 7, 2026 | Kathy Johnson WeilerDirector | Sold plan | 14,150 | $45.30 | $640,995 | Form 4 |
| May 8, 2026 | Amy McBride WendellDirector | Sold | 1,647 | $42.60 | $70,162 | Form 4 |
| May 7, 2026 | Kathy Johnson WeilerDirector | Sold | 16,344 | $44.09 | $720,607 | Form 4 |
| May 7, 2026 | John JohnsonDirector | Sold | 11,050 | $43.26 | $478,023 | Form 4 |
| May 7, 2026 | Jens KempChief Marketing Officer | Sold | 4,000 | $43.44 | $173,760 | Form 4 |
| May 7, 2026 | Doris QuackenbushSales VP | Sold | 3,878 | $43.51 | $168,732 | Form 4 |
| May 7, 2026 | Lindsey Marie HartleyCFO | Sold | 1,051 | $43.67 | $45,897 | Form 4 |
| Mar 16, 2026 | Erick Wayne DeVinneyChief Innovation Officer | Sold | 5,221 | $32.84 | $171,458 | Form 4 |
| Dec 16, 2025 | Kathy Johnson WeilerDirector | Sold | 46,653 | $29.55 | $1.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 6 of 9 | 5 of 9 |
| Rule of 40 | 2.4% | 18.6% | 18.9% |
| Altman Z'' | −2.48 | −1.47 | −0.43 |
| Accruals ratio | −8.2% | −7.2% | −7.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 6 of 9 | 5 of 9 |
Compare
Put Axogen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Axogen | FY25 | 20.2% | −3.5% | −1.3% | −4.9% | — | 5 | |
| Cerus | FY25 | 16.1% | −3.7% | 0.5% | — | — | — | Compare |
| Orthopediatrics | FY25 | 15.4% | −16.6% | −6.8% | −8.2% | — | 4 | Compare |
| STAAR Surgical | FY25 | −23.7% | −38.3% | −16.7% | — | — | — | Compare |
| Establishment Labs Holdings | FY25 | 27.1% | −18.5% | −27.0% | −39.0% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 41 | 60 | 84 | 107 | 112 | 127 | 139 | 159 | 187 | 225 |
| Revenue growth | 50.4% | 47.0% | 38.9% | 27.1% | 5.2% | 13.4% | 8.8% | 14.7% | 17.8% | 20.2% |
| Gross profit | 35 | 51 | 71 | 89 | 91 | 104 | 109 | 122 | 142 | 167 |
| Research and development | 4 | 7 | 12 | 18 | 18 | 24 | 26 | 27 | 28 | 33 |
| Operating income | −8 | −8 | −20 | −31 | −23 | −25 | −30 | −22 | −3 | −8 |
| Net income | −14 | −10 | −22 | −29 | −24 | −27 | −29 | −22 | −10 | −16 |
| Diluted EPS (US$) | −0.47 | −0.31 | −0.60 | −0.74 | −0.60 | −0.65 | −0.69 | −0.51 | −0.23 | −0.34 |
| Diluted shares (millions) | 31 | 33 | 37 | 39 | 40 | 41 | 42 | 43 | 44 | 46 |
| Cash flow | ||||||||||
| Cash from operations | −11 | −9 | −18 | −20 | −10 | −13 | −16 | −6 | 4 | 1 |
| Capital expenditure | 1 | 1 | 6 | 5 | 22 | 28 | 20 | 14 | 3 | 4 |
| Free cash flow | −12 | −10 | −24 | −25 | −32 | −41 | −36 | −20 | 1 | −3 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 4 | 8 | 10 | 8 | 11 | 16 | 14 | 16 | 30 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 30 | 36 | 117 | 96 | 104 | 84 | 49 | 31 | 34 | 42 |
| Debt incl. finance leases | 20 | 20 | 0 | 0 | 32 | 45 | 46 | 47 | 48 | 48 |
| Total assets | 46 | 59 | 160 | 155 | 201 | 208 | 195 | 197 | 204 | 222 |
| Total liabilities | 31 | 34 | 13 | 22 | 78 | 96 | 94 | 101 | 100 | 93 |
| Shareholders' equity | 15 | 25 | 147 | 132 | 123 | 112 | 101 | 96 | 104 | 129 |
| Margins and ratios | ||||||||||
| Gross margin | 84.3% | 84.6% | 84.6% | 83.7% | 80.8% | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Operating margin | −19.8% | −13.2% | −24.4% | −29.4% | −20.6% | −20.0% | −21.4% | −13.5% | −1.8% | −3.5% |
| Net margin | −35.1% | −17.3% | −26.7% | −27.3% | −21.2% | −21.2% | −20.9% | −13.7% | −5.3% | −7.0% |
| Free cash flow margin | −29.6% | −17.1% | −28.8% | −23.0% | −28.1% | −32.4% | −26.1% | −12.3% | 0.8% | −1.3% |
| Rule of 40 (growth + FCF margin) | 20.8% | 29.9% | 10.1% | 4.1% | −22.8% | −18.9% | −17.3% | 2.4% | 18.6% | 18.9% |
| Return on capital | −105.5% | −87.2% | −81.7% | −75.0% | −42.1% | −32.2% | −27.4% | −16.2% | −2.3% | −4.9% |
| Return on equity | −124.7% | −52.1% | −26.0% | −20.9% | −18.6% | −22.9% | −27.1% | −22.1% | −10.0% | −13.5% |
| Return on assets | −34.7% | −19.9% | −20.4% | −18.5% | −13.4% | −13.2% | −14.3% | −11.1% | −5.0% | −7.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | 4.4x | — |